Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tyrosinase Vaccine +/- IL-2 in Metastatic Melanoma
NCT00019734Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 1999
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase in melanoma, sponsored by National Cancer Institute. Started Jul 1999; status: completed.
02
Drugs
recombinant fowlpox-tyrosinase vaccinevaccinia-tyrosinase
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019734.